Entero Therapeutics (ENTO) SEC Filing Summary

Event Date: October 28, 2025 Subject: Nasdaq Listing Compliance Confirmation

• Nasdaq Compliance Achieved: Entero Therapeutics confirmed receipt of a letter from Nasdaq stating the Company is now in compliance with the minimum stockholders’ equity requirement (Listing Rule 5550(b)(1)).
• Basis for Compliance: Compliance resulted from the Share Exchange Agreement dated September 30, 2025, involving GridAI Corp.
• Key Warning: Nasdaq noted the Company must evidence continued compliance upon filing its *next perio